The Myopia Control Kit - Takeaways - MDSpire

The Myopia Control Kit

Thomas Aller, OD, provides in-depth overviews of each myopia management option—pharmacologic therapy, soft contact lenses, orthokeratology, spectacle lenses, and environmental and behavioral interventions—so clinicians can not only provide the right option to each patient, but also address the larger economic and societal burdens of myopia.

  • By

  • Thomas Aller, OD

  • May 1, 2026

  • 11 min

Share

  • 1

    Myopia is now recognized as a progressive disease with significant risks for ocular pathology, including retinal detachment and glaucoma.

  • 2

    Public health organizations advocate for myopia management to delay onset and slow progression, emphasizing its importance in standard eye care.

  • 3

    Economic modeling indicates that myopia incurs substantial productivity losses globally, affecting both individuals and society.

  • 4

    Low-dose atropine is a versatile pharmacologic therapy for myopia control, particularly effective in younger children and those with rapid progression.

  • 5

    Axial length measurements and the AL/CR ratio are critical for risk assessment in myopia management, aiding in early intervention decisions.

Original Source(s)

The Myopia Control Kit

  • by Thomas Aller, OD

  • May 1, 2026

Related Content

Epidemiology of eyelid disorders in an elderly population: Tehran Geriatric Eye Study

EGS Leaders Chart the Future of Glaucoma Care

Incoming and outgoing EGS presidents discuss the technologies, challenges, and priorities shaping the future of glaucoma care

The Evolving Glaucoma Toolbox

Justin Schweitzer, OD, FAAO, and Jessica Steen, OD, FAAO, describe emerging technologies, treatment strategies, and clinical considerations that can help eyecare professionals (ECPs) identify glaucoma earlier and better manage progression.